EUVIMEDEUVIMED entdecken
Crossref

In Brief: A New Indication for Dabrafenib (Tafinlar) and Trametinib (Mekinist) Combination Therapy

The Medical Letter on Drugs and Therapeutics · 2023

DOI: 10.58347/tml.2023.1669f ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, 2023. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The oral kinase inhibitors dabrafenib (Tafinlar – GSK) and trametinib (Mekinist – Novartis) have received accelerated approval by the FDA for use together for a fifth indication: treatment of unresectable or metastatic solid tumors with a BRAF V600E mutation in patients ≥6 years old who have progressed following prior treatment and have no satisfactory alternative treatment options.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaSkin NeoplasmsHumansPyridonesPyrimidinonesOximesProto-Oncogene Proteins B-rafAntineoplastic Combined Chemotherapy ProtocolsImidazoles

Stichwörter der Autor:innen

COVID-19Evusheldcilgavimabefficacytixagevimab

Substanzen

PyridonesPyrimidinonesOximesProto-Oncogene Proteins B-raftrametinibdabrafenibImidazoles

Zitieren

APA

(2023). In Brief: A New Indication for Dabrafenib (Tafinlar) and Trametinib (Mekinist) Combination Therapy. The Medical Letter on Drugs and Therapeutics. https://doi.org/10.58347/tml.2023.1669f

Vancouver

In Brief: A New Indication for Dabrafenib (Tafinlar) and Trametinib (Mekinist) Combination Therapy. The Medical Letter on Drugs and Therapeutics. 2023. doi:10.58347/tml.2023.1669f

BibTeX
@article{euvimed2023,
  title = {In Brief: A New Indication for Dabrafenib (Tafinlar) and Trametinib (Mekinist) Combination Therapy},
  journal = {The Medical Letter on Drugs and Therapeutics},
  year = {2023},
  doi = {10.58347/tml.2023.1669f}
}
Kostenlos starten →